{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T13:04:56Z","timestamp":1774789496091,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Roche Farmac\u00eautica e Qu\u00edmica Lda, Portugal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s41669-022-00381-z","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T13:53:36Z","timestamp":1669902816000},"page":"229-241","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal"],"prefix":"10.1007","volume":"7","author":[{"given":"Paulo","family":"Martins","sequence":"first","affiliation":[]},{"given":"Bj\u00f6rn","family":"Vandewalle","sequence":"additional","affiliation":[]},{"given":"Jorge","family":"F\u00e9lix","sequence":"additional","affiliation":[]},{"given":"Carlos M.","family":"Capela","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o J.","family":"Cerqueira","sequence":"additional","affiliation":[]},{"given":"Ant\u00f3nio V.","family":"Salgado","sequence":"additional","affiliation":[]},{"given":"Diana G.","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Isabel","family":"Monteiro","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"issue":"1","key":"381_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","volume":"26","author":"R Dobson","year":"2019","unstructured":"Dobson R, Giovannoni G. Multiple sclerosis\u2014a review. Eur J Neurol. 2019;26(1):27\u201340.","journal-title":"Eur J Neurol"},{"issue":"3","key":"381_CR2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278\u201386.","journal-title":"Neurology"},{"issue":"8","key":"381_CR3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1136\/jnnp-2016-315238","volume":"88","author":"HMB Lunde","year":"2017","unstructured":"Lunde HMB, et al. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. J Neurol Neurosurg Psychiatry. 2017;88(8):621\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"381_CR4","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1212\/WNL.46.4.907","volume":"46","author":"FD Lublin","year":"1996","unstructured":"Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907\u201311.","journal-title":"Neurology"},{"issue":"11","key":"381_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-041249","volume":"10","author":"I Gil-Gonz\u00e1lez","year":"2020","unstructured":"Gil-Gonz\u00e1lez I, et al. Quality of life in adults with multiple sclerosis: a systematic review. BMJ Open. 2020;10(11): e041249.","journal-title":"BMJ Open"},{"issue":"1","key":"381_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.euroneuro.2011.05.001","volume":"22","author":"P Jennum","year":"2012","unstructured":"Jennum P, et al. The socioeconomic consequences of multiple sclerosis: a controlled national study. Eur Neuropsychopharmacol. 2012;22(1):36\u201343.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"381_CR7","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s41669-020-00199-7","volume":"4","author":"O Heinzlef","year":"2020","unstructured":"Heinzlef O, et al. Economic burden of the out-of-pocket expenses for people with multiple sclerosis in France. PharmacoEconomics-Open. 2020;4(4):593\u2013603.","journal-title":"PharmacoEconomics-Open"},{"issue":"4","key":"381_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ana.24747","volume":"80","author":"University of California, S.F.M.E.T","year":"2016","unstructured":"University of California, S.F.M.E.T, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016;80(4):499\u2013510.","journal-title":"Ann Neurol"},{"issue":"2","key":"381_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, et al. ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler J. 2018;24(2):96\u2013120.","journal-title":"Mult Scler J"},{"issue":"9","key":"381_CR10","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s40263-018-0541-5","volume":"32","author":"RC Lucchetta","year":"2018","unstructured":"Lucchetta RC, et al. Disease-modifying therapies for relapsing\u2013remitting multiple sclerosis: a network meta-analysis. CNS Drugs. 2018;32(9):813\u201326.","journal-title":"CNS Drugs"},{"issue":"17","key":"381_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1212\/WNL.0000000000005345","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, et al. Comprehensive systematic review summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):789\u2013800.","journal-title":"Neurology"},{"issue":"3","key":"381_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221\u201334.","journal-title":"N Engl J Med"},{"issue":"3","key":"381_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209\u201320.","journal-title":"N Engl J Med"},{"key":"381_CR14","doi-asserted-by":"crossref","unstructured":"Vollmer T et al. Recently Diagnosed Early-Stage RRMS: NEDA, ARR, Disability Progression, Serum Neurofilament and Safety: 1-Year Interim Data From the Ocrelizumab Phase IIIb ENSEMBLE Study (2261). 2021, AAN Enterprises.","DOI":"10.1212\/WNL.96.15_supplement.2261"},{"issue":"12","key":"381_CR15","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S1474-4422(20)30342-2","volume":"19","author":"JS Wolinsky","year":"2020","unstructured":"Wolinsky JS, et al. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2020;19(12):998\u20131009.","journal-title":"Lancet Neurol"},{"issue":"13","key":"381_CR16","doi-asserted-by":"publisher","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","volume":"95","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, et al. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology. 2020;95(13):e1854\u201367.","journal-title":"Neurology"},{"key":"381_CR17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/B978-0-444-52001-2.00014-5","volume":"122","author":"C Confavreux","year":"2014","unstructured":"Confavreux C, Vukusic S. The clinical course of multiple sclerosis. Handb Clin Neurol. 2014;122:343\u201369.","journal-title":"Handb Clin Neurol"},{"issue":"6","key":"381_CR18","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40273-014-0150-1","volume":"32","author":"S Guo","year":"2014","unstructured":"Guo S, et al. Cost-effectiveness analyses in multiple sclerosis: a review of modelling approaches. Pharmacoeconomics. 2014;32(6):559\u201372.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"381_CR19","first-page":"iii","volume":"2","author":"D Parkin","year":"1998","unstructured":"Parkin D, et al. A cost-utility analysis of interferon beta for multiple sclerosis. Health Technol Assess (Winchester, Engl). 1998;2(4):iii\u201354.","journal-title":"Health Technol Assess (Winchester, Engl)"},{"issue":"03","key":"381_CR20","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1017\/S0266462300102041","volume":"16","author":"G Kobelt","year":"2000","unstructured":"Kobelt G, et al. Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis. Int J Technol Assess Health Care. 2000;16(03):768\u201380.","journal-title":"Int J Technol Assess Health Care"},{"issue":"3","key":"381_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40263-017-0412-5","volume":"31","author":"CE van Munster","year":"2017","unstructured":"van Munster CE, Uitdehaag BM. Outcome measures in clinical trials for multiple sclerosis. CNS Drugs. 2017;31(3):217\u201336.","journal-title":"CNS Drugs"},{"key":"381_CR22","doi-asserted-by":"publisher","DOI":"10.7175\/fe.v20i1.1435","author":"PA Cortesi","year":"2019","unstructured":"Cortesi PA, et al. The value and sustainability of ocrelizumab in relapsing multiple sclerosis: a cost-effectiveness and budget impact analysis. Farmeconomia. Health Econ Therap Pathways. 2019. https:\/\/doi.org\/10.7175\/fe.v20i1.1435.","journal-title":"Health Econ Therap Pathways"},{"issue":"10","key":"381_CR23","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1080\/13696998.2017.1355310","volume":"20","author":"H Yang","year":"2017","unstructured":"Yang H, et al. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis. J Med Econ. 2017;20(10):1056\u201365.","journal-title":"J Med Econ"},{"issue":"6","key":"381_CR24","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40273-020-00889-4","volume":"38","author":"P Auguste","year":"2020","unstructured":"Auguste P, et al. Ocrelizumab for treating patients with primary progressive multiple sclerosis: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2020;38(6):527\u201336.","journal-title":"Pharmacoeconomics"},{"key":"381_CR25","unstructured":"INFARMED I.P. Relat\u00f3rio de Avalia\u00e7\u00e3o Pr\u00e9via do Medicamento para Uso Humano em Meio Hospitalar; DCI - Ocrelizumab. 2020. https:\/\/www.infarmed.pt\/documents\/15786\/1424140\/Relat%C3%B3rio+p%C3%BAblico+de+avalia%C3%A7%C3%A3o+de+Medicamento+Ocrevus+%28DCI+ocrelizumab%29+2020\/5f7e7157-561c-6e22-5582-199404eedb1f. Accessed 18 June 2020."},{"issue":"11","key":"381_CR26","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444\u20131444.","journal-title":"Neurology"},{"key":"381_CR27","unstructured":"da Silva E et al. Orienta\u00e7\u00f5es metodol\u00f3gicas para estudos de avalia\u00e7\u00e3o econ\u00f3mica de medicamentos, in Autoridade Nacional do Medicamento e Produtos de Sa\u00fade IP. 1998."},{"issue":"1","key":"381_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004073","volume":"4","author":"J Palace","year":"2014","unstructured":"Palace J, et al. UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ Open. 2014;4(1): e004073.","journal-title":"BMJ Open"},{"issue":"7","key":"381_CR29","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1093\/brain\/awq118","volume":"133","author":"A Scalfari","year":"2010","unstructured":"Scalfari A, et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain. 2010;133(7):1914\u201329.","journal-title":"Brain"},{"issue":"4","key":"381_CR30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1600-0404.1982.tb03084.x","volume":"65","author":"U Patzold","year":"1982","unstructured":"Patzold U, Pocklington PR. Course of multiple sclerosis: first results of a prospective study carried out of 102 MS patients from 1976\u20131980. Acta Neurol Scand. 1982;65(4):248\u201366.","journal-title":"Acta Neurol Scand"},{"key":"381_CR31","first-page":"101","volume":"29","author":"RJ Pokorski","year":"1997","unstructured":"Pokorski RJ. Long-term survival experience of patients with multiple sclerosis. J Insurance Med N Y. 1997;29:101\u20136.","journal-title":"J Insurance Med N Y"},{"issue":"7","key":"381_CR32","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s00415-006-0132-0","volume":"253","author":"J De Sa","year":"2006","unstructured":"De Sa J, et al. The prevalence of multiple sclerosis in the District of Santarem, Portugal. J Neurol. 2006;253(7):914\u20138.","journal-title":"J Neurol"},{"issue":"2_suppl","key":"381_CR33","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/1352458517708667","volume":"23","author":"MJ S\u00e1","year":"2017","unstructured":"S\u00e1 MJ, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Portugal. Mult Scler J. 2017;23(2_suppl):143\u201354.","journal-title":"Mult Scler J"},{"key":"381_CR34","unstructured":"Statistics Portugal. Complete Life Tables Portugal 2015\u20132017. www.ine.pt. Accessed 29 Aug 2018."},{"key":"381_CR35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.msard.2018.12.040","volume":"29","author":"R McCool","year":"2019","unstructured":"McCool R, et al. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. Mult Scler Relat Disord. 2019;29:55\u201361.","journal-title":"Mult Scler Relat Disord"},{"key":"381_CR36","unstructured":"NICE The National Institute for Health and Care Excellence, Natalizumab for the treatment of adults with highly active relapsing\u2013remitting multiple sclerosis [TA127]."},{"issue":"1","key":"381_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1524-4733.2006.00144.x","volume":"10","author":"M Orme","year":"2007","unstructured":"Orme M, et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health. 2007;10(1):54\u201360.","journal-title":"Value Health"},{"issue":"5","key":"381_CR38","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/j.1524-4733.2007.00192.x","volume":"10","author":"D Tyas","year":"2007","unstructured":"Tyas D, et al. The distribution of the cost of multiple sclerosis in the UK: how do costs vary by illness severity? Value Health. 2007;10(5):386\u20139.","journal-title":"Value Health"},{"issue":"7","key":"381_CR39","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2165\/00019053-200826070-00008","volume":"26","author":"R Gani","year":"2008","unstructured":"Gani R, et al. Cost-effectiveness analyses of natalizumab (Tysabri\u00ae) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics. 2008;26(7):617\u201327.","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"381_CR40","doi-asserted-by":"publisher","first-page":"A727","DOI":"10.1016\/j.jval.2017.08.1973","volume":"20","author":"M Daigl","year":"2017","unstructured":"Daigl M, et al. Impact of disease activity measures on health utilities in PPMS. Value Health. 2017;20(9):A727\u20138.","journal-title":"Value Health"},{"key":"381_CR41","unstructured":"NICE The National Institute for Health and Care Excellence, Single technology appraisal: Ocrelizumab for treating primary progressive multiple sclerosis [TA585]\u2014company submission. 2018."},{"key":"381_CR42","unstructured":"NICE The National Institute for Health and Care Excellence, Daclizumab for treating relapsing\u2013remitting multiple sclerosis. Technology appraisal guidance [TA441]."},{"key":"381_CR43","unstructured":"PMH\u2014Portuguese Ministry of Health, Di\u00e1rio da Rep\u00fablica, 1.\u00aa s\u00e9rie\u2014N.\u00ba 132\u2014Portaria n.\u00ba 207\/2017 de 11 de Julho de 2017. 2018."},{"key":"381_CR44","unstructured":"SPMS\u2014Shared Services of the Portuguese Ministry of Health, Public Purchasing Catalogue."},{"issue":"2","key":"381_CR45","first-page":"205521731878334","volume":"4","author":"F Coret","year":"2018","unstructured":"Coret F, et al. Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies. Mult Scler J Exp Transl Clin. 2018;4(2):2055217318783347.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"4","key":"381_CR46","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/ene.14824","volume":"29","author":"H Butzkueven","year":"2022","unstructured":"Butzkueven H, et al. Risk of requiring a wheelchair in primary progressive multiple sclerosis: data from the ORATORIO trial and the MSBase registry. Eur J Neurol. 2022;29(4):1082\u201390.","journal-title":"Eur J Neurol"},{"issue":"6","key":"381_CR47","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40263-018-0530-8","volume":"32","author":"BM Uitdehaag","year":"2018","unstructured":"Uitdehaag BM. Disability outcome measures in phase III clinical trials in multiple sclerosis. CNS Drugs. 2018;32(6):543\u201358.","journal-title":"CNS Drugs"},{"issue":"4","key":"381_CR48","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s00415-019-09676-4","volume":"267","author":"N-H Ness","year":"2020","unstructured":"Ness N-H, et al. Differentiating societal costs of disability worsening in multiple sclerosis. J Neurol. 2020;267(4):1035\u201342.","journal-title":"J Neurol"},{"issue":"2","key":"381_CR49","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40273-017-0577-2","volume":"36","author":"S Iannazzo","year":"2018","unstructured":"Iannazzo S, Iliza A-C, Perrault L. Disease-modifying therapies for multiple sclerosis: a systematic literature review of cost-effectiveness studies. Pharmacoeconomics. 2018;36(2):189\u2013204.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"381_CR50","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jval.2018.08.011","volume":"22","author":"V Chirikov","year":"2019","unstructured":"Chirikov V, et al. Cost-effectiveness of alemtuzumab in the treatment of relapsing forms of multiple sclerosis in the United States. Value Health. 2019;22(2):168\u201376.","journal-title":"Value Health"},{"issue":"12","key":"381_CR51","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s40263-018-0566-9","volume":"32","author":"M Zimmermann","year":"2018","unstructured":"Zimmermann M, et al. Disease-modifying therapies for relapsing\u2013remitting and primary progressive multiple sclerosis: a cost-utility analysis. CNS Drugs. 2018;32(12):1145\u201357.","journal-title":"CNS Drugs"},{"issue":"2","key":"381_CR52","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40120-020-00212-5","volume":"9","author":"G Giovannoni","year":"2020","unstructured":"Giovannoni G, et al. A systematic review and mixed treatment comparison of pharmaceutical interventions for multiple sclerosis. Neurol Therapy. 2020;9(2):359\u201374.","journal-title":"Neurol Therapy"},{"issue":"6","key":"381_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102826","volume":"20","author":"Z Liu","year":"2021","unstructured":"Liu Z, et al. Disease modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. Autoimmun Rev. 2021;20(6): 102826.","journal-title":"Autoimmun Rev"},{"issue":"6","key":"381_CR54","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2217\/cer-2020-0267","volume":"10","author":"IA Samjoo","year":"2021","unstructured":"Samjoo IA, et al. Efficacy classification of modern therapies in multiple sclerosis. J Comp Eff Res. 2021;10(6):495\u2013507.","journal-title":"J Comp Eff Res"},{"issue":"2","key":"381_CR55","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/acn3.51282","volume":"8","author":"E Fernandez-Diaz","year":"2021","unstructured":"Fernandez-Diaz E, et al. Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population. Ann Clin Transl Neurol. 2021;8(2):385\u201394.","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"381_CR56","first-page":"639","volume":"27","author":"NJ Engmann","year":"2021","unstructured":"Engmann NJ, et al. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in US commercial claims data. J Manag Care Spec Pharm. 2021;27(5):639\u201349.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"381_CR57","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40120-020-00224-1","volume":"10","author":"EE Neuberger","year":"2021","unstructured":"Neuberger EE, et al. Work productivity outcomes associated with ocrelizumab compared with other disease-modifying therapies for multiple sclerosis. Neurol Therapy. 2021;10(1):183\u201396.","journal-title":"Neurol Therapy"},{"issue":"8","key":"381_CR58","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/13696998.2020.1761821","volume":"23","author":"J Nicholas","year":"2020","unstructured":"Nicholas J, et al. Real-world cost of treatment for multiple sclerosis patients initiating and receiving infused disease-modifying therapies per recommended label in the United States. J Med Econ. 2020;23(8):885\u201393.","journal-title":"J Med Econ"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-022-00381-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-022-00381-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-022-00381-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T20:03:16Z","timestamp":1728504196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-022-00381-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["381"],"URL":"https:\/\/doi.org\/10.1007\/s41669-022-00381-z","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]},"assertion":[{"value":"9 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by Roche Farmac\u00eautica e Qu\u00edmica, Lda., Portugal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"PM, BV and JF are employed by Exigo Consultores. The study sponsor contracted with Exigo Consultores for the development of the research project. Exigo Consultores provided support in the form of salaries for authors but did not have any additional role in the study design, data collection and analysis, or preparation of the manuscript. CC has received compensation for advisory board\/consulting services to Biogen, Janssen, Merck, Novartis, Roche, and Sanofi, and has been on the speakers\u2019 bureau for Almirall, Biogen, BMS, Janssen, Merck, Novartis, Roche, and Sanofi. JC has received compensation for activity with Almirall, Biogen, Bristol-Myers-Squibb, Janssen, Merck, Novartis, Roche, Sanofi, and Zambon. AS has received compensation for activity with Astra Zeneca, Biogen, Merck, Novartis, Roche, and Sanofi. DF and IM are employees of Roche Farmac\u00eautica e Qu\u00edmica, Lda., Portugal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication (from patients\/participants)"}},{"value":"All data and material relevant to the analysis are presented in the outlined publication or supplementary material. The model used in this study was provided to the journal\u2019s peer reviewers for their reference when reviewing the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The authors will answer any enquiries regarding the details of the analysis should these have not been answered by the information provided in the methods section.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability (software application or custom code)"}},{"value":"PM: study design, data collection, analytical calculations, interpretation of results, drafting and critical revision of the manuscript; BV: study design, interpretation of results and critical revision of the manuscript; JF: interpretation of results, drafting and critical revision of the manuscript; CMC: interpretation of results and critical revision of the manuscript; JJC: interpretation of results and critical revision of the manuscript; AVS: interpretation of results and critical revision of the manuscript; DGF: study conception, study design, interpretation of results, critical revision of the manuscript; IM: study conception, study design, interpretation of results, critical revision of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}